Chimeron Bio is pioneering a new era of targeted in-vivo genetic cell therapies using a proprietary, non-viral self-amplifying mRNA system engineered for precise, multiplexed gene delivery with highly durable expression (up to five weeks). Our approach overcomes the limitations of current LNP and viral technologies, enabling programmable immune-cell therapies with the potential for unprecedented clinical flexibility and safety for both oncology and auto-immune disorders.